...
首页> 外文期刊>Pathology oncology research: POR >Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.
【24h】

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.

机译:罗米洛司汀治疗套细胞淋巴瘤患者化疗诱导的血小板减少症(CIT)的疗效。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Chemotherapy induced thrombopenia (CIT) is difficult to treat, as previous treatment options, including recombinant human thrombopoietin proved to be of limited efficacy. Here we report a case of a mantle cell lymphoma patient treated with intensive chemotherapy, who belongs to Yehova's witnesses and therefore did not accept platelet transfusions. At the time of severe thrombocytopenia (zero thrombocytes/ per mikroliter) and gastrointestinal bleeding, on day 13 following the start of hyperCVAD B chemotherapy, romiplostim treatment was given resulting in quick normalisation of the platelet count followed by thrombocytosis. Based on our observation in further studies modification of the dose and timing of romiplostim injection in CIT should be considered.
机译:化学疗法诱发的血小板减少症(CIT)难以治疗,因为先前的治疗选择(包括重组人血小板生成素)被证明疗效有限。在这里,我们报道了一例经强化化疗治疗的套细胞淋巴瘤患者,该患者属于Yehova的证人,因此不接受血小板输注。在严重血小板减少症(血小板/每微克血小板数为零)和胃肠道出血时,hyperCVAD B化疗开始后的第13天,进行了romiplostim治疗,导致血小板计数快速正常化,继而发生血小板增多症。根据我们在进一步研究中的观察,应考虑在CIT中改用romiplostim注射剂量和时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号